Prot #R2810-ONC-1540: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Project: Research project

Project Details

StatusActive
Effective start/end date11/22/16 → 8/31/24

Funding

  • PPD Development (Prot #R2810-ONC-1540)
  • Regeneron Pharmaceuticals, Inc. (Prot #R2810-ONC-1540)